Madrigal Pharmaceuticals Inc
MDGL
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.9B
Close$
$1020.15
121.9% upside
Current Fair Value
121.9% upsideUndervalued by 121.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.90 Billion |
|---|---|
| Enterprise Value | $10.95 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.85 |
| Beta | -1.05 |
| Outstanding Shares | 29,145,271 |
Return
| Return on Equity | -62.07% |
|---|---|
| Return on Assets | -26.12% |
| Return on Invested Capital | -39.96% |
Valuation & Multiples
| P/E Ratio | -36.6 |
|---|---|
| PEG | -98.83 |
| Price to Sales | 10.45 |
| Price to Book Ratio | 27.05 |
| Enterprise Value to Revenue | 8.53 |
| Enterprise Value to EBIT | -31.5 |
| Enterprise Value to Net Income | -34 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.66 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-2.66
Average shareholder expectationRevenue Estimate
$350.85 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.83
Average shareholder expectationRevenue Estimate
$405.27 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 63.36% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 81.56% |
|---|---|
| Total Invested | $757,949▼ 99.99% |
| Investors Holding | 8▼ 431.00% |
ESG Score
No data
About Madrigal Pharmaceuticals Inc
CEO: Rebecca Taub